The American Cancer Society (ACS) and the Fanconi Cancer Foundation (FCF) invite translational cancer research proposals addressing the unique challenges faced by individuals with Fanconi anemia (FA), a rare inherited DNA repair disorder involving the FA/BRCA pathway. This high-risk, high-reward mechanism targets innovative ideas with clear potential to improve detection, prevention, or treatment of FA-associated cancers.
Eligibility Criteria:
-
Applicant must be an independent investigator (any career stage) with a full-time faculty appointment or equivalent at a US academic institution or eligible non-profit.
-
Applications may come from FA experts or investigators in related cancer biology pivoting to FA-relevant studies; proposals from researchers new to FA must demonstrate strong relevance and impact.
-
Applicants should review ACS/FCF grant policy eligibility requirements in the program’s grant policies document.
Funding Details:
-
Amount and term: up to USD 135,000 in direct costs per year for up to 2 years.
-
Indirect costs: up to 10% of direct costs.
-
Maximum total budget: USD 297,000 across a 2-year project.
-
Scientific scope priorities include early detection/biomarkers for FA-related squamous cell carcinomas, tumor prevention strategies, therapies tailored to FA sensitivity to DNA-damaging agents, novel disease models, and high-throughput/systems biology approaches to uncover FA-specific vulnerabilities.
Deadline:
-
RFA release: September 2025.
-
Application deadline: December 1, 2025.
-
Review period: February–March 2026.
-
Anticipated notification: August 2026.
-
Anticipated start date: October 1, 2026.
Where to go for further information:
-
Guidance: ACS Standard Application Instructions and program grant policies.
-
Program contact (email): [email protected].